These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

314 related articles for article (PubMed ID: 27745594)

  • 1. Nutrition Interventions in Chronic Kidney Disease.
    Anderson CA; Nguyen HA; Rifkin DE
    Med Clin North Am; 2016 Nov; 100(6):1265-1283. PubMed ID: 27745594
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dietary and pharmacological modification of fibroblast growth factor-23 in chronic kidney disease.
    Adema AY; de Borst MH; Ter Wee PM; Vervloet MG;
    J Ren Nutr; 2014 May; 24(3):143-50. PubMed ID: 24216259
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dietary recommendations for obese patients with chronic kidney disease.
    Anderson CA; Miller ER
    Adv Chronic Kidney Dis; 2006 Oct; 13(4):394-402. PubMed ID: 17045225
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Derangements in phosphate metabolism in chronic kidney diseases/endstage renal disease: therapeutic considerations.
    Molony DA; Stephens BW
    Adv Chronic Kidney Dis; 2011 Mar; 18(2):120-31. PubMed ID: 21406297
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Kidney and bone update : the 5-year history and future of CKD-MBD. Progress of phosphate binders].
    Hanba Y; Masumoto A; Moribata M; Shigemathu T
    Clin Calcium; 2012 Jul; 22(7):1059-71. PubMed ID: 22750939
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevention and treatment of protein energy wasting in chronic kidney disease patients: a consensus statement by the International Society of Renal Nutrition and Metabolism.
    Ikizler TA; Cano NJ; Franch H; Fouque D; Himmelfarb J; Kalantar-Zadeh K; Kuhlmann MK; Stenvinkel P; TerWee P; Teta D; Wang AY; Wanner C;
    Kidney Int; 2013 Dec; 84(6):1096-107. PubMed ID: 23698226
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hyperphosphatemia and phosphate binders: effectiveness and safety.
    Kalaitzidis RG; Elisaf MS
    Curr Med Res Opin; 2014 Jan; 30(1):109-12. PubMed ID: 24007207
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Niacin and Chronic Kidney Disease.
    Taketani Y; Masuda M; Yamanaka-Okumura H; Tatsumi S; Segawa H; Miyamoto K; Takeda E; Yamamoto H
    J Nutr Sci Vitaminol (Tokyo); 2015; 61 Suppl():S173-5. PubMed ID: 26598845
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of a non-calcium-based phosphate binder on fibroblast growth factor 23 in chronic kidney disease.
    Spatz C; Roe K; Lehman E; Verma N
    Nephron Clin Pract; 2013; 123(1-2):61-6. PubMed ID: 23774446
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)].
    Lorenzo Sellares V; Torregrosa V
    Nefrologia; 2008; 28 Suppl 3():67-78. PubMed ID: 19018742
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The "phosphorus pyramid": a visual tool for dietary phosphate management in dialysis and CKD patients.
    D'Alessandro C; Piccoli GB; Cupisti A
    BMC Nephrol; 2015 Jan; 16():9. PubMed ID: 25603926
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of aortic calcification with lanthanum carbonate vs. calcium-based phosphate binders in maintenance hemodialysis patients with type 2 diabetes mellitus: an open-label randomized controlled trial.
    Wada K; Wada Y
    Ther Apher Dial; 2014 Aug; 18(4):353-60. PubMed ID: 24417760
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [DIET CHARACTERISTICS IN PATIENTS WITH CHRONIC KIDNEY DISEASE].
    Bašić-Marković N; Šutić I; Popović B; Marković R; Vučak J
    Acta Med Croatica; 2016 Dec; 70(4-5):275-81. PubMed ID: 29087159
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Pleiotropic effects of sevelamer: a model of intestinal tract chelating agent].
    Massy ZA; Maizel J
    Nephrol Ther; 2014 Nov; 10(6):441-50. PubMed ID: 25070605
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Bone and Nutrition. Nutrition care of renal osteodystrophy].
    Tanaka S; Ito M
    Clin Calcium; 2015 Jul; 25(7):1057-62. PubMed ID: 26119320
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardiovascular disease in chronic kidney disease: risk factors, pathogenesis, and prevention.
    Ardhanari S; Alpert MA; Aggarwal K
    Adv Perit Dial; 2014; 30():40-53. PubMed ID: 25338421
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Latest consensus and update on protein-energy wasting in chronic kidney disease.
    Obi Y; Qader H; Kovesdy CP; Kalantar-Zadeh K
    Curr Opin Clin Nutr Metab Care; 2015 May; 18(3):254-62. PubMed ID: 25807354
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The MAURO study: baseline characteristics and compliance with guidelines targets.
    Leonardis D; Mallamaci F; Enia G; Postorino M; Tripepi G; Zoccali C;
    J Nephrol; 2012; 25(6):1081-90. PubMed ID: 23172127
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nutritional therapy, phosphate control and renal protection.
    Carrero JJ; Cozzolino M
    Nephron Clin Pract; 2014; 126(1):1-7. PubMed ID: 24434650
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Responsiveness of FGF-23 and mineral metabolism to altered dietary phosphate intake in chronic kidney disease (CKD): results of a randomized trial.
    Sigrist M; Tang M; Beaulieu M; Espino-Hernandez G; Er L; Djurdjev O; Levin A
    Nephrol Dial Transplant; 2013 Jan; 28(1):161-9. PubMed ID: 23024219
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.